JeffreyCrawfordMD

Professor of Medicine George Barth Geller Professor Member of the Duke Cancer Institute Associate Director of Clinical Research, Comprehensive Cancer Center

Join to view full profile

Dr. Crawford is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Crawford's full profile

Already have an account?

Office
Duke Medical Ctr
Durham, NC 27710
Phone+1 919-620-4467

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1979 - 1982
Duke University HospitalResidency, Internal Medicine, 1978 - 1979
Duke University HospitalFellowship, Hematology and Medical Oncology, 1977 - 1978
Duke University HospitalResidency, Internal Medicine, 1974 - 1977
Ohio State University College of MedicineClass of 1974

Certifications & Licensure

NC State Medical License 1974 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer Start of enrollment: 2009 Feb 01
Unknown status
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations Start of enrollment: 2012 Mar 16
Completed
Phase 2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Start of enrollment: 2013 Jul 31
Completed
Phase 2
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Start of enrollment: 2017 Mar 24
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis.
Cameron Wood, Liliana Lyniv, James M Isaacs, Jacob M Kaufman, Eziafa I Oduah
Journal for Immunotherapy of Cancer. 2025-02-04
1 citations
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.
Jeffrey M Clarke, George R Simon, Hirva Mamdani, Lin Gu, James E Herndon 2nd
Nature Communications. 2025-01-02
10 citations
Ponsegromab for the Treatment of Cancer Cachexia.
John D Groarke, Jeffrey Crawford, Susie M Collins, Shannon Lubaczewski, Eric J Roeland
The New England Journal of Medicine. 2024-12-19

Lectures

5th Symposium on Emerging Treatments & Advances in Novel Cancer Therapies for Practicing Physicians & Healthcare Professionals
CancerNet, LLC, Dallas, Texas - 1/18/2012

Press Mentions

Will Ponsegromab Be a Game Changer for Cancer Cachexia?October 17th, 2024
Novel Agent Effective for Cancer Wasting DisorderSeptember 18th, 2024
Pfizer: Potential Cachexia Cancer Drug Shows Life-Saving PromiseSeptember 14th, 2024
Join now to see all